Timothy M. Mayleben's most recent trade in Marinus Pharmaceuticals Inc was a trade of 4,980 Common Stock done . Disclosure was reported to the exchange on Oct. 10, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals Inc | Mayleben Timothy M. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Oct 2024 | 4,980 | 13,957 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Mayleben Timothy M. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Oct 2024 | 1,660 | 10,637 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Mayleben Timothy M. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Oct 2024 | 1,660 | 12,297 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 10,450 | 10,450 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 2,300 | 24,375 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Mayleben Timothy M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Mayleben M. Timothy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 4,600 | 22,075 (0%) | 0% | 0 | Common Stock | |
| Landos Biopharma Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 16,200 | 16,200 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 3,600 | 17,475 (0%) | 0% | 0 | Common Stock | |
| Landos Biopharma Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 12,375 | 12,375 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 2,750 | 13,875 (0%) | 0% | 0 | Common Stock | |
| Landos Biopharma Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Timothy M. Mayleben | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Marinus Pharmaceuticals Inc | Timothy M. Mayleben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 16,500 | 16,500 | - | - | Stock option (right to buy) | |
| Esperion Therapeutics Inc. | Timothy M. Mayleben | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2020 | 10,700 | 262,959 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Timothy M. Mayleben | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 30 Dec 2020 | 10,700 | 122,698 (0%) | 0% | 2.1 | 22,427 | Common Stock |